An observational study in Type 1 Diabetes Mellitus, sponsored by Institut de Recherches Cliniques de Montreal. Recruiting at 7 sites in Canada. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Institut de Recherches Cliniques de Montreal · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Institut de Recherches Cliniques de Montreal.
Among the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, this one is one of 5 that started in 2019, is one of 4 observational ones, and was the 27th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →8 of the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal are open now, in 1 country. Recruiting first, the newest first:
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+ · Healthy volunteers
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 50+ · Women only
Institut de Recherches Cliniques de Montreal
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 20 · Phase 4 1
First in 2012; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 38 interventional studies, 88 across the 4 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut de Recherches Cliniques de Montreal is the lead sponsor of 61 studies on the registry; 11 are open to participants now.
4 of the studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06683391Institut de Recherches Cliniques de MontrealUpdating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living with Type 1 Diabetes | 2026-12-31 |
| NCT07491133Institut de Recherches Cliniques de MontrealEffect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes | 2027-03 |
| NCT03720197Institut de Recherches Cliniques de MontrealRegistry of Patients Living with Type 1 Diabetes | 2027-03-31 |
| NCT07475962Institut de Recherches Cliniques de MontrealPrevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc.
Participation to the registry is divided in 3 phases. The first phase is mandatory for all participants. Phases 2 and 3 are optional.
The objective of phase 1 is to draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications. It takes about 10 minutes to answer the questionnaire. If the participant uses a continuous glucose monitor and agrees, the participant is invited to send the latest report of the continuous glucose monitor.
The objective of phase 2 is to characterize the causes, experience and consequences of hypoglycemia. Phase 2 also involves, if the participant accepts and live in the province of Quebec or Alberta, to provide the research team with their latest blood and urine tests as well as their list of medications.
The objective of phase 3 is to collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia. Phase 3 also involves, if the participant agrees, answering a food questionnaire, wearing a step counter, measuring waist circumference
Individuals with type 1 diabetes living in Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Online questionnaire - Phase 1 · Other: Continuous glucose monitor
Other: Online questionnaire - Phase 1 · Other: Online questionnaire - Phase 2 · Other: Online questionnaire - Phase 3 · Other: Food questionnaire · Other: Pedometer · Other: Waist circumference · Other: Blood and urine tests · Other: List of medications · Other: Continuous glucose monitor
Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
Characterize the causes, experience and consequences of hypoglycemia.
Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
24-hour food recall questionnaire
Participants will wear a podometer for 14 consecutives days
Participants will be asked to measure their waist circumference
Participants will be invited to send us their latests blood and urine test results.
Participants will be invited to send us their list of medications
Participants will be invited to send us the latest report of their continuous glucose monitor
Number of non-severe hypoglycemic episodes
Participants will be asked to report the number of non-severe hypoglycemic episodes in the last 12 months in a questionnaire designed by the investigators. The definition of non-severe hypoglycemia is a blood sugar below 3.0 mmol/L that the participant was able to treat himself
Time frame: 12 months
Number of severe hypoglycemic episodes
Participants will be asked to report the number of severe hypoglycemic episodes in the last 12 months in a questionnaire designed by the investigators. The definition of severe hypoglycemia is low blood sugar levels requiring help from another person or use of glucagon or hospitalization or loss of consciousness.
Time frame: 12 months
Fear of hypoglycemia
Fear of hypoglycemia will be assessed by the Hypoglycemia Fear Survey II.
Time frame: 6 months
Diabetes distress
Diabetes distress will be assessed by the Diabetes Distress Scale.
Time frame: 1 month
Medical follow-up for diabetes
Participants will be asked to report in a questionnaire designed by the investigators how many times in the last 12 months they have seen a health care professionals (family doctor, medical specialist, nurse, nutritionnist, kinesiologist, psychologist, pharmacist, social worker).
Time frame: 12 months
Insulin doses
Participants will be asked to report in a questionnaire designed by the investigators their insulin doses of the last 3 days (basal insulin and insulin given at mealtime).
Time frame: 3 days
Physical activity
Physical activity will be assessed by the International Physical Activity Questionnaire.
Time frame: 1 week
Sleep habits
Sleep habits will be assessed by the Pittsburgh Sleep Quality Index
Time frame: 1 month
Depression
Depression will be assessed by the Patient Health Questionnaire (PHQ-9)
Time frame: 2 weeks
Number of steps
The number of steps will be measured by a pedometer
Time frame: 14 days
Plan to share: No
Started Feb 2019 (actual). Primary completion is estimated for Mar 2027, 97 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 97 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Recherches Cliniques de Montreal